PlainPharmaWatch

CMS Open Payments · Program Year 2024

BeiGene USA, Inc.

BeiGene USA, Inc. reported $13,442,558.01 across General Payments, Research, and Ownership to 11,760 physicians and teaching hospitals across 12,014 transactions.

$13.4M Top 10% payer
All-tracks total
12,014 Top 10% volume
Transactions
11,760 Top 10% reach
Recipients
+$16.7K
General Payments vs PY2023

BeiGene USA, Inc. reported $13,442,558.01 across all CMS Open Payments tracks (General + Research + Ownership) to 11,760 physicians and teaching hospitals in Program Year 2024 - ranking #139 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $3,373,619.09, averaging $1.1K per recipient.

How BeiGene USA, Inc.'s $13.4M all-tracks total breaks down

BeiGene USA, Inc.'s payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

A

93/100

Total payments

A

100/100

Transaction volume

A

97/100

Physician reach

A

99/100

Payment type diversity

C

77/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer beigene-usa-inc BeiGene USA, Inc.

$13.4M · #139/1,925 · 0.1% industry · PY2024

  • TOT $13.4M
  • RANK #139
  • SHARE 0.1%
  • TXN 12,014
  • RCP 11,760
  • CAT 6
  • GEN $3.4M
  • ΔGEN +$16.7K
  • TOP1 7.4%
  • PY 2024

Nearest volume peer: Ultradent Products Inc ($13.4M)

Centinel Spine, LLC$13.6MBlueprint Medicines Corporat…$13.5MUltradent Products Inc$13.4MBeiGene USA, Inc. (this)$13.4MAlcon Vision LLC$13.4M
All-tracks payment totals near BeiGene USA, Inc. (CMS Open Payments PY2024)

BeiGene USA, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

BeiGene USA, Inc.'s CMS-reported General Payments increased by $16.7K (+0.5%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: BEIGENE USA, INC.PY2023: BEIGENE USA, INC.PY2024: BeiGene USA, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$3.4MPY2024$3.4M
PY2023
$3,356,935.98
PY2024
$3,373,619.09

What the Data Shows for BeiGene USA, Inc.

Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For BeiGene USA, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.

Of the 6 general-payment categories charted below, "Compensation for Services Other Than Consulting" is the largest at $1.6M across 421 transactions, 46.7% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

BeiGene USA, Inc. made 6 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $1.6M, 46.7% of General Payments.

BeiGene USA, Inc. reports 6 general-payment categories - the top three are Compensation for Services Other Than Consulting (46.7%), Consulting Fee (26.6%), and Food and Beverage (11.3%). The remaining 3 categories make up 15.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How BeiGene USA, Inc. divides its payments

Top payment categories by total reported dollar volume

1. Compensation for Services…$1.6M2. Consulting Fee$896.6K3. Food and Beverage$382.3K4. Grant$299.8K5. Travel and Lodging$219.4K6. Education$41.21
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $1.6M 421
Consulting Fee $896.6K 519
Food and Beverage $382.3K 10,295
Grant $299.8K 2
Travel and Lodging $219.4K 522
Education $41.21 1

Recipient Concentration in General Payments

The five largest recipient relationships account for $570,909.72 (16.9%) of $3,373,619.09 in this company's General Payments records across 5,687 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for BeiGene USA, Inc.

The five named recipients with the highest reported General Payments from this company

Dana-Farber Cancer Institute$250.0KImadeddine Tabbara$88.1KAndrew Whiteley$81.9KCatherine C Coombs$76.5KHakan Kaya$74.4K
  1. 1

    Dana-Farber Cancer Institute

    $250,000.00 across 1 reported transactions

  2. 2

    Imadeddine Tabbara

    $88,106.05 across 49 reported transactions

  3. 3

    Andrew Whiteley

    $81,945.85 across 46 reported transactions

  4. 4

    Catherine C Coombs

    $76,490.97 across 59 reported transactions

  5. 5

    Hakan Kaya

    $74,366.85 across 55 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

BeiGene USA, Inc. ranks #139 of 1,925 by total payments (top 7% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,647 of 1,838 by HHI (bottom 10% least concentrated), a wider distribution than most similarly sized payers.

02.65.37.910.5122.5125.3128130.8133.5Total payments ($M)Concentration (HHI, 0-10,000)
BeiGene USA, Inc. (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as BeiGene USA, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about BeiGene USA, Inc..

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with BeiGene USA, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

BeiGene USA, Inc. ranks #139 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download BeiGene USA, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.